Heart Rate Changes During Normal Activity, Exercise, and Sleep in Normal Healthy Subjects With and Without Epilepsy

Completed

• Conditions: Healthy; Exercise

• Registration Number: NCT01202682
• Lead Sponsor: Cyberonics, Inc.

Brief Summary

The purpose of this study is to gather ECG data during normal activity, exercise, and sleep from normal subjects with or without well-controlled epilepsy. This normal subject data will serve as "true negative" (i.e., no seizure occurring) challenge data for testing cardiac based seizure detection algorithms.

Detailed Description

The purpose of this study is to gather ECG data during normal activity, exercise, and sleep from normal subjects with or without well-controlled epilepsy. This normal subject data will serve as "true negative" (i.e., no seizure occurring) challenge data for testing cardiac based seizure detection algorithms.

Study Timeline

• Status Verified: 2010-09
• Study Start: 2010-09
• Study First Submitted: 2010-09-14
• Study First Submitted QC: 2010-09-15
• Study First Posted: 2010-09-16
• Primary Completion: 2010-10
• Study Completion: 2010-10
• Last Update Submitted: 2011-01-20
• Last Update Posted: 2011-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Subjects must be 18 years or older and may be of either sex and of any race.
2. Subject must be in good general health, fully ambulatory, and able to complete the physical aspects of testing requirements.
3. Subject must be willing and able to complete informed consent and HIPAA authorization.
4. Subject may be diagnosed with epilepsy but must be well controlled on their regular treatment regimen.
5. Women of childbearing potential must have a negative urine pregnancy test.

Exclusion Criteria

1. Subjects with skin abnormalities or conditions that would interfere with ECG electrode patch placement or cause subject discomfort with patch placement.
2. Subjects report history of allergies or sensitivity to adhesive tapes or patches.
3. Subjects with severe psychiatric disease that in the investigator's judgment would prevent the subject's successful completion of the study.
4. Subjects with epilepsy experiencing status epilepticus within the last 6 months.
5. Subjects with cardiovascular, respiratory, neuromuscular or gait disorders that in the investigator's judgment would cause unnecessary risk or inability to participate in the protocol.
6. Subjects with known cardiovascular arrhythmias or cardiac disease resulting in history of cardiac disease or abnormal ECG recordings. These include, but are not limited to, conditions such as chronic atrial fibrillation and permanent cardiac pacemaker implantation.
7. Use of beta adrenergic antagonists (i.e., "beta blockers") or calcium channel blocker agents that may affect heart rate.
8. Subjects currently dependent on alcohol or narcotic drugs as defined by DSM IV-TR.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Clinical Trials of Texas; 🇺🇸 San Antonio, Texas, United States